Navigation Links
UCSD Health Sciences partners with Pfizer to speed drug delivery
Date:8/8/2011

In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer's Centers for Therapeutic Innovation (CTI).

"The collaborative partnerships formed through the Centers for Therapeutic Innovation between Pfizer and academic medical centers such as UC San Diego allow leading medical and clinical experts to join with Pfizer's highly skilled scientists using Pfizer's resources and expertise and each institution's advanced drug development capabilities to speed the translation of innovative science into medicine for patients," said Jose Carlos Gutierrez-Ramos, PhD, senior vice president and head of BioTherapeutics Research and Development for Pfizer.

CTI differs from other such programs that seek to drive innovation in drug discovery by providing a non-traditional business model based on continuous collaboration and transparency, one which offers well-defined incentives for success to its participants. For example, as part of the CTI program, Pfizer will provide UC San Diego researchers access to some of its antibody libraries and technologies, as well as funding to support the pre-clinical and clinical development of sponsored programs. CTI partners receive intellectual property rights and are granted milestone payments and royalties tied to the advancement of mutually agreed-upon drug candidates. The potential value to UC San Diego over the five-year agreement could exceed $50 million.

"Public-private partnerships are increasingly important in science, especially in an era of limited federal grant support, when new resources are needed to commercialize innovations related to health care," said UC San Diego Chancellor Marye Anne Fox. "The UC San Diego-Pfizer agreement is an example of how we can work together and will hopefully serve as a model for other collaborations with industry."

According to Gary S. Firestein, MD, dean and associate vice chancellor of Translational Medicine and director of the Clinical and Translational Research Institute (CTRI) at UC San Diego School of Medicine, the collaboration utilizes UC San Diego's medical research strengths in key areas including neurosciences, cancer, inflammation, metabolism, clinical pharmacology, HIV and pain. It will also build upon efforts of the School of Medicine's expanding CTRI, launched in 2010 to emphasize interdisciplinary collaboration among UCSD scientists and develop innovative approaches to solve difficult medical challenges. Last year, the CTRI received a five-year, $37.2 million award from the National Center for Research Resources, part of the National Institutes of Health an award also designed to improve biomedical research by accelerating the application of laboratory discoveries into effective treatment for patients, more actively engaging communities in clinical research and training future generations of researchers.

David Brenner, MD, vice chancellor for health sciences and dean of the School of Medicine at UC San Diego, concurred that more research collaborations between academia and industry will be critical in the face of the uncertain support from the state and federal government.

"As medical science evolves and grows, the demand for creative research projects such as this agreement with Pfizer and the need for people who can translate this basic research into real, beneficial therapies and treatments will only increase," said Brenner. "From the UC San Diego Moores Cancer Center and the many other leading-edge research institutes on campus, to our deep involvement in major clinical trials and status as one of the nation's top teaching hospitals, UC San Diego has established itself as a vital hub for this kind of innovative work. The Pfizer collaboration allows us, with CTRI leading the way, to push ahead in new and even more imaginative ways to advance medical research."

CTI laboratory staff will include Pfizer employees plus leading basic and translational science investigators and doctoral candidates from UC San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences, along with other UCSD researchers in biological sciences, bioengineering and at the California Institute for Telecommunications and Information Technology (Calit2).

"The CTI model offers leading investigators the resources to pursue scientific and clinical breakthroughs by providing access to select Pfizer compound libraries, proprietary screening methods, and antibody development technologies that are directly relevant to the investigators' work," said Firestein, adding the hoped-for result will be better testing of clinical hypotheses, increasing the speed with which medicines can be delivered to patients in need.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. Weight loss improves sexual health of overweight men with diabetes
2. Study suggests increase in public health spending results in healthier people
3. Health Plans Much Costlier for Docs in U.S. Than Canada: Study
4. US physicians spend nearly 4 times more on health insurance costs than Canadian counterparts
5. Group Health establishes major initiative to prevent opioid abuse and overdose
6. Genes, Not Healthy Living, Get Most to Age 100
7. Kids Still See Unhealthy-Food Ads on TV, Study Finds
8. More Families Turning to Public Plans for Childrens Health Care
9. Colon Cleansing Has No Health Benefit, May Harm: Report
10. U.S. to Pay Bigger Share of Rising Cost of Health Care
11. New global health delivery curricula
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from PsychTests.com reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Marcy was in a crisis. Her son James, ... out at his family verbally and physically. , “When something upset him, he couldn’t control ... use it. He would throw rocks at my other children and say he was going ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... D.C. (PRWEB) , ... June 24, 2016 , ... ... Heroes Golf Classic Tournament held on June 20th at the Woodmont Country Club ... charity, Luke’s Wings, an organization dedicated to helping service members that have been wounded ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: